| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | tamo; C16orf76 |
| WB Predicted band size | 46 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human SPATA2L |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SPATA2L抗体的3篇参考文献的简要列举(注：SPATA2L研究较为小众，以下内容为模拟示例，实际文献需通过学术数据库验证)：
---
1. **标题**: *"SPATA2L modulates necroptosis by regulating CYLD activity through direct interaction"*
**作者**: Yang C, et al.
**摘要**: 本研究揭示了SPATA2L通过结合去泛素化酶CYLD调控细胞程序性坏死的分子机制。作者利用SPATA2L特异性抗体进行免疫共沉淀实验，证实其与CYLD的相互作用，并发现SPATA2L缺失可增强TNF-α诱导的坏死性凋亡。
---
2. **标题**: *"Characterization of SPATA2L as a novel biomarker in hepatocellular carcinoma"*
**作者**: Li X, Wang Y, Zhang H.
**摘要**: 通过免疫组化(使用抗SPATA2L抗体)和qRT-PCR分析，发现SPATA2L在肝癌组织中高表达，且与患者预后不良相关。实验表明SPATA2L通过促进肿瘤细胞增殖和迁移参与肝癌进展。
---
3. **标题**: *"SPATA2L regulates mitochondrial dynamics via binding to Drp1"*
**作者**: Kim S, et al.
**摘要**: 该研究利用SPATA2L抗体进行Western blot和免疫荧光实验，证明SPATA2L通过与线粒体分裂蛋白Drp1结合，调控线粒体形态和功能，其缺失导致线粒体碎片化加剧及细胞能量代谢异常。
---
提示：实际研究中SPATA2L相关文献有限，建议通过PubMed或Web of Science以“SPATA2L antibody”或“SPATA2L function”为关键词检索最新成果。部分研究可能未直接提及抗体，但会涉及该蛋白的功能验证。
SPATA2L (Spermatogenesis-Associated Protein 2-Like) is a relatively understudied protein implicated in cellular processes such as apoptosis, inflammation, and ubiquitination pathways. It shares homology with SPATA2. a known regulator of the CYLD-RIPK1 signaling complex, which modulates NF-κB activation and necroptosis. SPATA2L is hypothesized to interact with similar molecular partners, potentially influencing cell survival and death mechanisms. However, its precise biological functions and regulatory mechanisms remain unclear.
SPATA2L antibodies are essential tools for investigating the protein's expression, localization, and interactions in various tissues and disease models. These antibodies are typically developed in immunized host species (e.g., rabbits or mice) using peptide antigens derived from conserved regions of the human SPATA2L protein. Validation often includes Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to confirm specificity and cross-reactivity across species.
Research utilizing SPATA2L antibodies has linked the protein to cancer progression, neurodegenerative disorders, and male infertility, though evidence is preliminary. For instance, altered SPATA2L expression has been observed in certain tumors, suggesting a role in oncogenic signaling or therapy resistance. Additionally, its potential involvement in ubiquitin-dependent pathways highlights its relevance in proteostasis and inflammation-related diseases. Further studies with high-quality antibodies are critical to unraveling SPATA2L's functional significance and therapeutic potential.
×
